can semaglutide cause breast cancer Cancer? Know the Potential GLP-1 Risks Case-Based Review of Breast Imaging

As the first triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, it offers a unique mechanism of action with complementary effects on multiple aspects of metabolism

extending into the early 2030s, Novo Nordisk's core semaglutide patent has lapsed in Canada

7) Monitor for nutrient gaps

For GLP-1 users, those outcomes are not theoretical, they map directly onto daily challenges around energy dips, under-eating and nutritional adequacy.

Losing muscle is

A large international study suggests that a subset of people with Type 2 diabetes carry genetic variants that blunt the effectiveness of widely used GLP-1based drugs, despite unexpectedly elevated levels of the hormone in their bodies